Business Wire

IL-ISACA

16.9.2021 19:23:08 CEST | Business Wire | Press release

Share
ISACA to Host Inaugural ISACA Conference Europe Virtual Event

Next month, ISACA will host the first-ever ISACA Conference Europe , an event focused on emerging technologies, best practices, and leadership development. The conference will take place virtually 20-22 October featuring topics for business technology professionals as they navigate their transformational roles.

ISACA Conference Europe sessions range from 25-75 minutes in length and provide the opportunity to earn up to 19 continuing professional education credits. Conference tracks focus on IT audit, IT governance, COBIT, CMMI, cybersecurity, privacy, risk, performance improvement, emerging technologies, and leadership development & career management.

Sessions will be presented live via ISACA’s virtual conference platform, and many will feature a live Q&A with speakers. Attendees will have extended access to the sessions and content so they may view them at their own pace. Session topics include data ethics laws, blockchain, CMMI V2.0, cloud security, auditing artificial intelligence, quantum computing, privacy compliance, and much more.

Opening keynote speaker Dr. Beau Lotto, neuroscientist and world-renowned expert in perception, will share why trading certainty for doubt increases our capacity to adapt, lead, innovate, and thrive in the darkness of "I don’t know." Magician and entrepreneur Vinh Giang will use the themes of perspective, empowerment, goal setting, and positive mindset during his keynote to encourage attendees to believe in positive changes in their lives and business ventures. Shivvy Jervis, founder of the FutureScape 248 lab, will close the event with her keynote on the intersection of digital breakthroughs, scientific discoveries, and brain chemistry and how they can elevate business and our future.

One In Tech , an ISACA Foundation, will host a workshop, “Allies Required: Your Role in the Evolving Digital Trust Workforce,” which will discuss the importance of allies and advocates in advancing diversity, equity and inclusion within an organization. Participants will learn more about the role of an ally and how they can use the tools provided in the session to proactively and routinely champion inclusion.

ISACA Conference Europe encompasses topics previously found at ISACA events like CACS, CSX and Capability Counts. More details and registration for the conference can be found at https://www.isaca.org/conferences/isaca-conference-europe . Companies interested in participating as a sponsor can contact sponsorship@isaca.org .

ISACA has additional offerings this quarter, including:

  • Virtual Instructor-Led Training and Training Weeks
    • Advancing Your IT Auditing Skills, 20-24 September
    • Data Analytics and Visualization for Auditors, 27-30 September
    • IoT Fundamentals, 14-15 October
    • Privacy and Data Protection Simulation, 18-21 October
  • Training Week in New Orleans, LA, USA , 6-9 December, featuring exam preparation for CISM, CISA, Cybersecurity Fundamentals, and Data Science Fundamentals. This is an in-person event with safety practices in place: masks are required, and the classrooms will allow for optimized social distancing.
  • Free webinars on topics including securing hybrid environments, ISACA’s blockchain framework, building operational resilience, managing third-party risk, and active directory security.

ISACA will also host EVOLVE , its first-ever emerging tech conference, taking place virtually 16-17 November.

For more information, visit: https://www.isaca.org/training-and-events/ .

About ISACA

For more than 50 years, ISACA® has equipped individuals with knowledge, credentials, education and community to progress their careers and transform their organizations, and enabled enterprises to train and build quality teams. ISACA leverages the expertise of its more than 150,000 members who work in information security, governance, assurance, risk and privacy to drive innovation through technology. It has a presence in 188 countries, including more than 220 chapters. In 2020, ISACA launched One In Tech, a philanthropic foundation.

Link:

ClickThru

Social Media:

https://www.facebook.com/ISACAGlobal/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye